A new Schaeffer Center white paper demonstrates why meaningful 340B reform must end “spread pricing,” in which participating providers buy discounted drugs and bill insurers at higher rates. The post Reform of Federal Drug Discount Program Should Target Misaligned Incentives appeared first on USC Schaeffer.
